Completed enrollment in soquelitinib atopic dermatitis Phase 1 trial extension cohort 4 (200 mg BID dose with 8-week treatment period) with data announcement anticipated in January Soquelitinib atopic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback